HOME » NEWS AND TRENDS


Novo Nordisk Gets Close to Launching the First Oral GLP-1 Drug for Diabetes

BY ALEXANDER BURIK 23/02/2018 - 3 MINUTES V in 🛛 🛇

Novo Nordisk has positive Phase III trial results for its oral version of semaglutide, a GLP-1 based treatment for type II diabetes. This could be the first oral GLP-1 treatment on the market, making it easier for patients to take the drug.

After obtaining approval for an injected version, **Novo Nordisk** is now getting ready to launch what could be the first oral version of a GLP-1 drug to treat type 2 diabetes. **Glucagon-like peptide (GLP)** -1 receptor agonists are a key innovation in firstline treatments for type II <u>diabetes</u>. They act by increasing the body's levels of **insulin**, a hormone that lowers blood sugar levels, while decreasing levels of glucagon, produced by the body a hormone that increases blood sugar levels. Novo Nordisk's oral **semaglutide** is a GLP-1 analogue taken once daily as a tablet, which would be more convenient for patients than treatments administered by injections. The Phase III results show that **80% of patients** receiving the highest dose had **low long-term blood sugar levels**, compared to 34% of patients treated with placebo. If launched, it may be the first oral GLP-1 treatment for type 2 diabetes to enter the market.

Out of the contenders in the GLP-1 treatment market, Novo Nordisk's injected version of semaglutide along with Eli Lilly's Trulicity stand out because they only need to be administered by injection once a week. Importantly, the <u>injected</u> <u>version of semaglutide</u> sets itself apart from Trulicity through greater **reductions in blood sugar** and double the amount of **weight loss**. Novo's oral version of semaglutide could make the treatment even more accessible to patients.



Eli Lilly remains confident in their market position, though, <u>stating</u> Novo will be competing with other, **non-oral diabetes treatments**, such as Jardiance and Merck's Steglatro. But these drugs have a different mechanism of action, targeting a molecule known as **SGLT2** to prevent the kidneys from reabsorbing sugar into the blood. Semaglutide's GLP-1 mechanism of action may be more effective, since its **double action** of increasing insulin and decreasing glucagon could result in a more widespread lowering of blood sugar levels.

Related Content

Needle-Free Diabetes Care: 7 Devices that Painlessly Monitor Blood Sugar

CLARA RODRÍGUEZ FERNÁNDEZ 28 SEPTEMBER 2021

Needle-Free Diabetes Care: 7 Devices that Painlessly Monitor Blood Sugar

CLARA RODRÍGUEZ FERNÁNDEZ 28 SEPTEMBER 2021

Novo faces competition from other contenders as well. Last year, **Zealand Pharma** and **Sanofi** launched **Suliqua** in the US as a treatment for type 2 diabetes. Suliqua uses a combination long-acting insulin and the GLP-1 receptor agonist lixisenatide. However, the **market landscape** for diabetes treatment is constantly changing. **Intarcia**, a US biotech, had to terminate two Phase III trials in January after the FDA rejected its drug-delivery device for type 2 diabetes. Images by ESB Professional, Eviart/Shutterstock

Related Content

Growth Hormone Deficiency Gets FDA Nod JONATHAN SMITH 1 SEPTEMBER 2021

Slow-Release Jab for Child Behind the Scenes at Novo Seeds: Building Startups from the Ground up HELEN ALBERT 23 AUGUST 2021

Explore Related Topics: Diabetes Drug delivery \mathfrak{V} in \bowtie (S) Eli Lilly Intarcia Sanofi

You might also be interested in the following:

UK Startup Surfs Investment Wave in Microbiome with €18M Series A ANITA CHAKRAVERTY 15 SEPTEMBER 2021 How Digital Solutions Are Transforming Biomanufacturing

MAYA CHERGOVA 12 AUGUST 2021

The 21 European Biotech Companies to Watch in 2021 LARISSA WARNECK

11 AUGUST 2021

Europe's Antibiotic Investments Stagnate As Resistance Crisis Looms JONATHAN SMITH 21 SEPTEMBER 2021 UK Venture Round Shines Spotlight on Europe's Psychedelics Scene JONATHAN SMITH 24 AUGUST 2021

More from Labiotech

NEWS AND TRENDS

Exscientia IPO Attracts Tech Investor Bets to AI Drug Discovery

Support Us

Become a Member

((💋))

.eu

Labiotech.eu is the leading digital media covering the European Biotech industry.

Over 150,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you'll enjoy reading our stories!

About us	in	Linkedin
Inside Labiotech	y	Twitter
Join Us	D	Youtube
Advertise	9	RSS Feed
Contact		
Site Map		

Made with V in Berlin. Labiotech UG, All Rights Reserved - Imprint Privacy Policy